Diabetes, Vol 33, Issue 4 346-354, Copyright © 1984 by American Diabetes Association

ARTICLES

The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects

OG Kolterman, RS Gray, G Shapiro, JA Scarlett, J Griffin and JM Olefsky

Although sulfonylurea agents have been used in the clinical management of type II diabetes (non-insulin-dependent diabetes mellitus, NIDDM) for over two decades, the mechanisms responsible for their hypoglycemic action remain controversial. We have quantitated glycemic control, endogenous insulin secretion in response to mixed meals, adipocyte insulin binding, insulin-mediated peripheral glucose disposal, and basal hepatic glucose output in 17 type II diabetic subjects before and after 3 mo of therapy with the second-generation, sulfonylurea compound glyburide in an attempt to identify the factors responsible for the clinical response to the drug. In addition, 9 subjects were treated for an additional 15 mo to see if the response to the drug changed with time. The mean fasting serum glucose level fell from an initial value of 264 +/- 17 mg/dl to 178 +/- 16 mg/dl after 3 mo of drug therapy. Endogenous insulin secretion increased in all subjects, but the increase was most marked in those subjects who continued to exhibit fasting hyperglycemia (fasting serum glucose greater than 175 mg/dl) after 3 mo of therapy. Adipocyte insulin binding was unchanged after 3 mo of therapy, while the maximal rate of peripheral glucose disposal was increased by 23%, indicating enhancement of peripheral insulin action at a postreceptor site(s). Basal hepatic glucose output showed a significant correlation with the fasting serum glucose level both before and after therapy (r = 0.86, P less than 0.001) and fell from 141 +/- 12 mg/m2/min before therapy to 107 +/- 11 mg/m2/min after 3 mo of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S Bolkent, R Yanardag, O Karabulut-Bulan, and O Ozsoy-Sacan The morphological and biochemical effects of glibornuride on rat liver in experimental diabetes Human and Experimental Toxicology, May 1, 2004; 23(5): 257 - 264. [Abstract] [PDF]

				E. Rodriguez, N. Pulido, R. Romero, F. Arrieta, A. Panadero, and A. Rovira Phosphatidylinositol 3-Kinase Activation Is Required for Sulfonylurea Stimulation of Glucose Transport in Rat Skeletal Muscle Endocrinology, February 1, 2004; 145(2): 679 - 685. [Abstract] [Full Text] [PDF]

				N. Kumar and C. S. Dey Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells J. Exp. Biol., December 1, 2002; 205(23): 3739 - 3746. [Abstract] [Full Text] [PDF]

				D. Overkamp, A. Volk, E. Maerker, P. E. Heide, H. G. Wahl, K. Rett, and H. U. Haring Acute Effect of Glimepiride on Insulin-Stimulated Glucose Metabolism in Glucose-Tolerant Insulin-Resistant Offspring of Patients With Type 2 Diabetes Diabetes Care, November 1, 2002; 25(11): 2065 - 2073. [Abstract] [Full Text] [PDF]

				M. Korytkowski, A. Thomas, L. Reid, M. B. Tedesco, W. E. Gooding, and J. Gerich Glimepiride Improves Both First and Second Phases of Insulin Secretion in Type 2 Diabetes Diabetes Care, September 1, 2002; 25(9): 1607 - 1611. [Abstract] [Full Text] [PDF]

				S. E. Kahn The Importance of {beta}-Cell Failure in the Development and Progression of Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4047 - 4058. [Full Text] [PDF]

				M. Gaster, P. Staehr, H. Beck-Nielsen, H. D. Schrøder, and A. Handberg GLUT4 Is Reduced in Slow Muscle Fibers of Type 2 Diabetic Patients: Is Insulin Resistance in Type 2 Diabetes a Slow, Type 1 Fiber Disease? Diabetes, June 1, 2001; 50(6): 1324 - 1329. [Abstract] [Full Text]

				M. L. Hribal, R. D'Alfonso, B. Giovannone, D. Lauro, Y. Y. Liu, P. Borboni, M. Federici, R. Lauro, and G. Sesti The Sulfonylurea Glimepiride Regulates Intracellular Routing of the Insulin-Receptor Complexes through Their Interaction with Specific Protein Kinase C Isoforms Mol. Pharmacol., February 1, 2001; 59(2): 322 - 330. [Abstract] [Full Text]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				K. L. Jones Non-Insulin Dependent Diabetes in Children and Adolescents: The Therapeutic Challenge Clinical Pediatrics, February 1, 1998; 37(2): 103 - 110. [Abstract] [PDF]

				D. E. Baker and R. K. Campbell The Second Generation Sulfonylureas: Glipizide and Glyburide The Diabetes Educator, September 1, 1985; 11(3): 29 - 36. [PDF]

				R. K. Miyahara Pharmacotherapy of Oral Hypoglycemic Agents Clin-Alert, January 1, 1973; 11(1): 271 - 279. [Abstract] [PDF]